United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Nepsis Inc.

Nepsis Inc. increased its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 58,574 shares of the biotechnology company's stock after purchasing an additional 3,653 shares during the quarter. United Therapeutics accounts for 4.5% of Nepsis Inc.'s portfolio, making the stock its 9th largest position. Nepsis Inc. owned about 0.13% of United Therapeutics worth $18,057,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Wealthfront Advisers LLC raised its holdings in United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the period. Norges Bank purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $151,764,000. FMR LLC grew its stake in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after acquiring an additional 393,777 shares during the period. GAMMA Investing LLC increased its holdings in United Therapeutics by 29,415.2% in the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock worth $68,422,000 after acquiring an additional 221,202 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in United Therapeutics by 1,325.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock worth $72,085,000 after acquiring an additional 189,967 shares during the period. Institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Bank of America cut their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday. Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Finally, Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $393.08.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer now owns 8,118 shares in the company, valued at $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 68,500 shares of company stock worth $20,828,390. Company insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 0.2%

Shares of UTHR traded up $0.46 during trading on Friday, reaching $286.60. 158,498 shares of the company traded hands, compared to its average volume of 451,176. The stock has a 50-day simple moving average of $300.43 and a 200-day simple moving average of $331.51. The stock has a market cap of $12.93 billion, a PE ratio of 12.56, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same period last year, the company earned $6.17 earnings per share. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.